For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...
Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...
Everyday Health on MSN
MASH: Is semaglutide right for you?
Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH treatment plan.
Zacks Investment Research on MSN
CHMP backs higher-dose Wegovy as Novo Nordisk seeks 2026 EU approval
Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...
Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...
GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...
Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback